Literature DB >> 25724666

βIII-Tubulin Regulates Breast Cancer Metastases to the Brain.

Deepak Kanojia1, Ramin A Morshed1, Lingjiao Zhang1, Jason M Miska1, Jian Qiao1, Julius W Kim1, Peter Pytel2, Irina V Balyasnikova1, Maciej S Lesniak3, Atique U Ahmed1.   

Abstract

Brain metastases occur in about 10% to 30% of breast cancer patients, which culminates in a poor prognosis. It is, therefore, critical to understand the molecular mechanisms underlying brain metastatic processes to identify relevant targets. We hypothesized that breast cancer cells must express brain-associated markers that would enable their invasion and survival in the brain microenvironment. We assessed a panel of brain-predominant markers and found an elevation of several neuronal markers (βIII-tubulin, Nestin, and AchE) in brain metastatic breast cancer cells. Among these neuronal predominant markers, in silico analysis revealed overexpression of βIII-tubulin (TUBB3) in breast cancer brain metastases (BCBM) and its expression was significantly associated with distant metastases. TUBB3 knockdown studies were conducted in breast cancer models (MDA-Br, GLIM2, and MDA-MB-468), which revealed significant reduction in their invasive capabilities. MDA-Br cells with suppressed TUBB3 also demonstrated loss of key signaling molecules such as β3 integrin, pFAK, and pSrc in vitro. Furthermore, TUBB3 knockdown in a brain metastatic breast cancer cell line compromised its metastatic ability in vivo, and significantly improved survival in a brain metastasis model. These results implicate a critical role of TUBB3 in conferring brain metastatic potential to breast cancer cells. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25724666      PMCID: PMC4425587          DOI: 10.1158/1535-7163.MCT-14-0950

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  39 in total

1.  Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series.

Authors:  Christine Desmedt; Fanny Piette; Sherene Loi; Yixin Wang; Françoise Lallemand; Benjamin Haibe-Kains; Giuseppe Viale; Mauro Delorenzi; Yi Zhang; Mahasti Saghatchian d'Assignies; Jonas Bergh; Rosette Lidereau; Paul Ellis; Adrian L Harris; Jan G M Klijn; John A Foekens; Fatima Cardoso; Martine J Piccart; Marc Buyse; Christos Sotiriou
Journal:  Clin Cancer Res       Date:  2007-06-01       Impact factor: 12.531

Review 2.  Microtubules and resistance to tubulin-binding agents.

Authors:  Maria Kavallaris
Journal:  Nat Rev Cancer       Date:  2010-02-11       Impact factor: 60.716

3.  Prognostic role of platinum sensitivity in patients with brain metastases from ovarian cancer: results of a German multicenter study.

Authors:  J Sehouli; K Pietzner; P Harter; K Münstedt; S Mahner; A Hasenburg; O Camara; P Wimberger; D Boehmer; K J Buehling; R Richter; K El Khalfaoui; G Oskay-Ozcelik
Journal:  Ann Oncol       Date:  2010-05-03       Impact factor: 32.976

4.  Gender influences the class III and V β-tubulin ability to predict poor outcome in colorectal cancer.

Authors:  Marisa Mariani; Gian Franco Zannoni; Stefano Sioletic; Steven Sieber; Candice Martino; Enrica Martinelli; Claudio Coco; Giovanni Scambia; Shohreh Shahabi; Cristiano Ferlini
Journal:  Clin Cancer Res       Date:  2012-03-21       Impact factor: 12.531

5.  Metastatic sites and survival in lung cancer.

Authors:  M Riihimäki; A Hemminki; M Fallah; H Thomsen; K Sundquist; J Sundquist; K Hemminki
Journal:  Lung Cancer       Date:  2014-08-02       Impact factor: 5.705

6.  Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10.

Authors:  Pascal Sève; Raymond Lai; Keyue Ding; Timothy Winton; Charles Butts; John Mackey; Charles Dumontet; Laith Dabbagh; Sarit Aviel-Ronen; Lesley Seymour; Marlo Whitehead; Ming-Sound Tsao; Frances A Shepherd; Tony Reiman
Journal:  Clin Cancer Res       Date:  2007-02-01       Impact factor: 12.531

Review 7.  Movers and shakers: cell cytoskeleton in cancer metastasis.

Authors:  C M Fife; J A McCarroll; M Kavallaris
Journal:  Br J Pharmacol       Date:  2014-07-02       Impact factor: 8.739

Review 8.  L1CAM: a major driver for tumor cell invasion and motility.

Authors:  Helena Kiefel; Sandra Bondong; John Hazin; Johannes Ridinger; Uwe Schirmer; Svenja Riedle; Peter Altevogt
Journal:  Cell Adh Migr       Date:  2012-07-01       Impact factor: 3.405

9.  CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFβ signaling.

Authors:  P-K Lo; D Kanojia; X Liu; U P Singh; F G Berger; Q Wang; H Chen
Journal:  Oncogene       Date:  2011-09-26       Impact factor: 9.867

10.  Inhibition of type I insulin-like growth factor receptor signaling attenuates the development of breast cancer brain metastasis.

Authors:  Sandra M Saldana; Heng-Huan Lee; Frank J Lowery; Yekaterina B Khotskaya; Weiya Xia; Chenyu Zhang; Shih-Shin Chang; Chao-Kai Chou; Patricia S Steeg; Dihua Yu; Mien-Chie Hung
Journal:  PLoS One       Date:  2013-09-05       Impact factor: 3.240

View more
  22 in total

1.  High αv Integrin Level of Cancer Cells Is Associated with Development of Brain Metastasis in Athymic Rats.

Authors:  Yingjen Jeffrey Wu; Michael A Pagel; Leslie L Muldoon; Rongwei Fu; Edward A Neuwelt
Journal:  Anticancer Res       Date:  2017-08       Impact factor: 2.480

2.  Microarray expression profiling identifies genes, including cytokines, and biofunctions, as diapedesis, associated with a brain metastasis from a papillary thyroid carcinoma.

Authors:  Hans-Juergen Schulten; Deema Hussein; Fatima Al-Adwani; Sajjad Karim; Jaudah Al-Maghrabi; Mona Al-Sharif; Awatif Jamal; Sherin Bakhashab; Jolanta Weaver; Fahad Al-Ghamdi; Saleh S Baeesa; Mohammed Bangash; Adeel Chaudhary; Mohammed Al-Qahtani
Journal:  Am J Cancer Res       Date:  2016-10-01       Impact factor: 6.166

Review 3.  Breast cancer brain metastasis: molecular mechanisms and directions for treatment.

Authors:  Rute M S M Pedrosa; Dana A Mustafa; Riccardo Soffietti; Johan M Kros
Journal:  Neuro Oncol       Date:  2018-10-09       Impact factor: 12.300

4.  Nucleoporin-93 reveals a common feature of aggressive breast cancers: robust nucleocytoplasmic transport of transcription factors.

Authors:  Nishanth Belugali Nataraj; Ashish Noronha; Joo Sang Lee; Soma Ghosh; Harsha Raj Mohan Raju; Arunachalam Sekar; Binyamin Zuckerman; Moshit Lindzen; Emilio Tarcitano; Swati Srivastava; Michael Selitrennik; Ido Livneh; Diana Drago-Garcia; Oscar Rueda; Carlos Caldas; Sima Lev; Tamar Geiger; Aaron Ciechanover; Igor Ulitsky; Rony Seger; Eytan Ruppin; Yosef Yarden
Journal:  Cell Rep       Date:  2022-02-22       Impact factor: 9.423

5.  Investigation of the effects of overexpression of jumping translocation breakpoint (JTB) protein in MCF7 cells for potential use as a biomarker in breast cancer.

Authors:  Madhuri Jayathirtha; Anca-Narcisa Neagu; Danielle Whitham; Shelby Alwine; Costel C Darie
Journal:  Am J Cancer Res       Date:  2022-04-15       Impact factor: 5.942

6.  2-(m-Azidobenzoyl)taxol binds differentially to distinct β-tubulin isotypes.

Authors:  Chia-Ping Huang Yang; Eng-Hui Yap; Hui Xiao; Andras Fiser; Susan Band Horwitz
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-20       Impact factor: 11.205

7.  BET inhibition increases βIII-tubulin expression and sensitizes metastatic breast cancer in the brain to vinorelbine.

Authors:  Deepak Kanojia; Wojciech K Panek; Alex Cordero; Jawad Fares; Annie Xiao; Solomiia Savchuk; Krishan Kumar; Ting Xiao; Katarzyna C Pituch; Jason Miska; Peng Zhang; Kwok-Ling Kam; Craig Horbinski; Irina V Balyasnikova; Atique U Ahmed; Maciej S Lesniak
Journal:  Sci Transl Med       Date:  2020-08-26       Impact factor: 17.956

8.  Intuitive repositioning of an anti-depressant drug in combination with tivozanib: precision medicine for breast cancer therapy.

Authors:  Naveen Kumar; Masoom Raza; Seema Sehrawat
Journal:  Mol Cell Biochem       Date:  2021-07-29       Impact factor: 3.396

9.  Nestin Is Required for Spindle Assembly and Cell-Cycle Progression in Glioblastoma Cells.

Authors:  Qinglin Wang; Hao Wu; Jian Hu; Haijuan Fu; Yanghui Qu; Yijun Yang; Kathy Q Cai; Andrey Efimov; Minghua Wu; Tim Yen; Yuan Wang; Zeng-Jie Yang
Journal:  Mol Cancer Res       Date:  2021-06-22       Impact factor: 5.852

10.  Multimodal evaluation of hypoxia in brain metastases of lung cancer and interest of hypoxia image-guided radiotherapy.

Authors:  Samuel Valable; Jade Fantin; Aurélien Corroyer-Dulmont; Laurent Chatre; Jérôme Toutain; Sylvain Teulier; Céline Bazille; Elise Letissier; Jérôme Levallet; Didier Divoux; Méziane Ibazizène; Stéphane Guillouet; Cécile Perrio; Louisa Barré; Sébastien Serres; Nicola R Sibson; Françoise Chapon; Guénaëlle Levallet; Myriam Bernaudin
Journal:  Sci Rep       Date:  2021-05-27       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.